Molecule intelOpportunity: ModerateEssentialCrowded market

Levetiracetam

403 brands · 101 companies · product forms

ATC: N03AX14 1 DRAP alert

Opportunity snapshot

Launch attractiveness
49
Market saturation
100
Price room
100
Regulatory risk
50
403
brands
101
companies
Rs 1,425.11
median price
552
price points
48.61x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 3%

Price room

Across observed sources and strengths
CheapestRs 194.19
MedianRs 1,425.11
Most expensiveRs 9,439.88
Spread48.61×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 48.61x across 552 trusted points (Rs 194.19-9439.88). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Levetiracetam — each links to its own medicine page.

Regulatory alerts

Recall exposureSafety exposurelatest 2025-10-08
RAPID ALERT: UNREGISTERED & SUBSTANDARD — LEVITRA 20 mg TABLET (Batch BXNZ2488)

Why this score

Launch attractiveness

40% supply-gap(45) + 25% price-variation(100) + 20% low-competition(0) + 15% supply-disruption(40), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

101 canonical companies and 403 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 48.61x across 552 trusted points (Rs 194.19-9439.88). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

1 DRAP alert(s), latest 2025-10-08 incl. recall/safety.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.